Singh Rakesh K, Lange Thilo S, Kim Kyu Kwang, Shaw Sunil K, Brard Laurent
Molecular Therapeutics Laboratory, Program in Women's Oncology, Department of Obstetrics and Gysnecology, Women and Infants' Hospital, Brown University, Providence, RI 02905, USA.
Gynecol Oncol. 2008 May;109(2):240-9. doi: 10.1016/j.ygyno.2008.01.042. Epub 2008 Mar 7.
A novel indole ethyl isothiocyanate derivative (7Me-IEITC) was defined as a potent growth-suppressing agent to cell lines derived from ovarian cancers. Key mechanisms of the cellular response in vitro were studied and suggest a potential of 7Me-IEITC as a therapeutic drug.
The viability of ovarian cancer cell lines (SKOV-3, OVCAR-3) in comparison to pancreatic and prostate cancer cell lines, primary fibroblast and immortalized trophoblasts after treatment with 7Me-IEITC was analyzed. Morphological and apoptotic responses of SKOV-3 were studied by fluorescence microscopy (DAPI staining, TUNEL assay). SKOV-3 proliferation was estimated by a standardized BrdU incorporation assay. The phosphorylation of MAP-Kinases, pro-survival factors and the activation of caspases and PARP-1 were analyzed by western blotting. Changes of the mitochondrial transmembrane-potential and in cell-cycle progression were studied by FACS analysis. MAP-Kinase and caspase inhibitors were employed in cytotoxicity studies.
7Me-IEITC selectively reduced the viability of SKOV-3, OVCAR-3, BXPC-3 and PC-3 cells (IC(50) values < or = 5 microM), while the viability of fibroblasts or trophoblasts remained un-affected at concentrations below 20 microM. 7Me-IEITC treatment down-regulated pro-survival kinases and transcription factors (STAT-3, IKKalpha and NF-kappaB), caused rapid loss of the mitochondrial transmembrane-potential and inactivation of PARP-1 along with activation of caspases. The use of p38 MAP-Kinase-and caspase inhibitors suppressed the cytotoxicity of the drug. 7Me-IEITC acted as an anti-proliferative agent and arrested the cell-cycle progression of SKOV-3 in G2/M phase.
7Me-IEITC is a potent and growth-suppressing agent to cell lines derived from ovarian cancers by causing deactivation of survival signals, apoptosis, and cell-cycle arrest.
一种新型吲哚乙基异硫氰酸酯衍生物(7Me-IEITC)被确定为对源自卵巢癌的细胞系具有强效生长抑制作用的药物。研究了其体外细胞反应的关键机制,并表明7Me-IEITC具有作为治疗药物的潜力。
分析了7Me-IEITC处理后卵巢癌细胞系(SKOV-3、OVCAR-3)与胰腺和前列腺癌细胞系、原代成纤维细胞及永生化滋养层细胞的活力。通过荧光显微镜(DAPI染色、TUNEL检测)研究SKOV-3的形态和凋亡反应。通过标准化的BrdU掺入试验评估SKOV-3的增殖。通过蛋白质印迹法分析丝裂原活化蛋白激酶(MAP激酶)、促生存因子的磷酸化以及半胱天冬酶和聚(ADP-核糖)聚合酶-1(PARP-1)的激活情况。通过流式细胞术分析线粒体跨膜电位的变化和细胞周期进程。在细胞毒性研究中使用了MAP激酶和半胱天冬酶抑制剂。
7Me-IEITC选择性降低了SKOV-3、OVCAR-3、BXPC-3和PC-3细胞的活力(半数抑制浓度(IC50)值≤5微摩尔),而在浓度低于20微摩尔时,成纤维细胞或滋养层细胞的活力未受影响。7Me-IEITC处理下调了促生存激酶和转录因子(信号转导子和转录激活子3(STAT-3)、核因子κB抑制蛋白激酶α(IKKα)和核因子κB(NF-κB)),导致线粒体跨膜电位迅速丧失、PARP-1失活以及半胱天冬酶激活。使用p38 MAP激酶和半胱天冬酶抑制剂可抑制该药物的细胞毒性。7Me-IEITC作为一种抗增殖剂,使SKOV-3的细胞周期进程停滞在G2/M期。
7Me-IEITC通过使生存信号失活、诱导凋亡和细胞周期停滞,对源自卵巢癌的细胞系具有强效生长抑制作用。